Insider Buying: Perspective Therapeutics, Inc. (NYSE:CATX) CFO Buys 1,800 Shares of Stock

Perspective Therapeutics, Inc. (NYSE:CATX) CFO Jonathan Robert Hunt bought 1,800 shares of the firm’s stock in a transaction dated Monday, June 17th. The stock was purchased at an average price of $9.81 per share, with a total value of $17,658.00. Following the completion of the purchase, the chief financial officer now directly owns 35,971 shares of the company’s stock, valued at approximately $352,875.51. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Jonathan Robert Hunt also recently made the following trade(s):

• On Friday, May 31st, Jonathan Robert Hunt bought 2,500 shares of Perspective Therapeutics stock. The stock was purchased at an average price of $14.00 per share, with a total value of $35,000.00.

Perspective Therapeutics Stock Up 3.0 %

Shares of CATX traded up $0.31 during midday trading on Tuesday, hitting $10.65. The stock had a trading volume of 147,552 shares, compared to its average volume of 477,043. Perspective Therapeutics, Inc. has a fifty-two week low of $2.05 and a fifty-two week high of $19.05. The company has a current ratio of 12.98, a quick ratio of 12.98 and a debt-to-equity ratio of 0.01.

Perspective Therapeutics (NYSE:CATX) last posted its quarterly earnings results on Wednesday, May 15th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.10. The business had revenue of $0.33 million during the quarter. Perspective Therapeutics had a negative net margin of 302.70% and a negative return on equity of 46.38%. As a group, equities analysts anticipate that Perspective Therapeutics, Inc. will post -0.11 earnings per share for the current year.

Institutional Trading of Perspective Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. Virtu Financial LLC bought a new position in Perspective Therapeutics during the first quarter valued at approximately $138,000. Janus Henderson Group PLC bought a new position in shares of Perspective Therapeutics in the first quarter valued at approximately $15,511,000. Affinity Asset Advisors LLC bought a new position in shares of Perspective Therapeutics in the first quarter valued at approximately $6,069,000. Vanguard Group Inc. raised its position in shares of Perspective Therapeutics by 34.6% in the first quarter. Vanguard Group Inc. now owns 17,780,106 shares of the company’s stock valued at $21,158,000 after purchasing an additional 4,566,356 shares during the period. Finally, Bleakley Financial Group LLC bought a new position in shares of Perspective Therapeutics in the first quarter valued at approximately $40,000. 54.66% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts have recently weighed in on the stock. Oppenheimer restated an “outperform” rating and issued a $15.00 target price (up from $12.00) on shares of Perspective Therapeutics in a research note on Monday, April 1st. Cantor Fitzgerald reiterated an “overweight” rating on shares of Perspective Therapeutics in a research note on Tuesday. B. Riley increased their target price on shares of Perspective Therapeutics from $12.00 to $17.00 and gave the stock a “buy” rating in a report on Tuesday, April 9th. Lifesci Capital reissued an “outperform” rating on shares of Perspective Therapeutics in a report on Monday, May 6th. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $30.00 target price on shares of Perspective Therapeutics in a report on Friday. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Perspective Therapeutics has a consensus rating of “Buy” and an average price target of $19.00.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.